期刊
CONTRAST MEDIA & MOLECULAR IMAGING
卷 7, 期 2, 页码 254-264出版社
WILEY-HINDAWI
DOI: 10.1002/cmmi.491
关键词
HER2; Lutetium-177; nanobody; breast cancer; bifunctional chelator
资金
- SCK.CEN/VUB
- Vlaamse Liga Tegen Kanker
- Interuniversity Attraction Poles Program, Belgian State, Belgian Science Policy
- Nationaal Kankerplan Action [29]
- FWO-Vlaanderen [G.013910]
Nanobodies show favourable pharmacokinetic characteristics for tumor targeting, including high tumor-to-background-ratios. Labelled with a therapeutic radionuclide, nanobodies could be used as an adjuvant treatment option for HER2-overexpressing minimal residual disease. The therapeutic radionuclide Lutetium-177 is linked to the nanobody using a bifunctional chelator. The choice of the bifunctional chelator could affect the in vivo behaviour of the radiolabeled nanobody. Consequently, we compared four different bifunctional chelators - p-SCN-Bn-DOTA, DOTA-NHS-ester, CHX-A-DTPA or 1B4M-DTPA - in order to select the optimal chemical link between Lutetium-177 and a HER2 targeting nanobody.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据